Home Other Building Blocks Treosulfan

Treosulfan

CAS No.:
299-75-2
Catalog Number:
AG00BF51
Molecular Formula:
C6H14O8S2
Molecular Weight:
278.3006
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
98%
1 week
United States
$175
- +
10mg
98%
1 week
United States
$251
- +
50mg
98%
1 week
United States
$821
- +
100mg
98%
1 week
United States
$1376
- +
Product Description
Catalog Number:
AG00BF51
Chemical Name:
Treosulfan
CAS Number:
299-75-2
Molecular Formula:
C6H14O8S2
Molecular Weight:
278.3006
MDL Number:
MFCD02258964
IUPAC Name:
[(2S,3S)-2,3-dihydroxy-4-methylsulfonyloxybutyl] methanesulfonate
InChI:
InChI=1S/C6H14O8S2/c1-15(9,10)13-3-5(7)6(8)4-14-16(2,11)12/h5-8H,3-4H2,1-2H3/t5-,6-/m0/s1
InChI Key:
YCPOZVAOBBQLRI-WDSKDSINSA-N
SMILES:
O[C@H]([C@H](COS(=O)(=O)C)O)COS(=O)(=O)C
EC Number:
206-081-0
UNII:
CO61ER3EPI
Properties
Complexity:
345  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
2  
Defined Bond Stereocenter Count:
0
Exact Mass:
278.013g/mol
Formal Charge:
0
Heavy Atom Count:
16  
Hydrogen Bond Acceptor Count:
8  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
278.29g/mol
Monoisotopic Mass:
278.013g/mol
Rotatable Bond Count:
7  
Topological Polar Surface Area:
144A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
-2.2  
Literature
Title Journal
Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. Bone marrow transplantation 20121001
Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning. Bone marrow transplantation 20120901
Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor. Annals of hematology 20120801
A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis. Journal of cancer research and clinical oncology 20120801
Nonmyeloablative conditioning generates autoantigen-encoding bone marrow that prevents and cures an experimental autoimmune disease. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20120801
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 20120712
HPLC method for determination of biologically active epoxy-transformers of treosulfan in human plasma: pharmacokinetic application. Journal of pharmaceutical and biomedical analysis 20120325
Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike. Bone marrow transplantation 20120101
Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. Annals of hematology 20120101
Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine. European journal of haematology 20120101
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone marrow transplantation 20111201
CD40 ligand deficiency with grade III liver fibrosis, transplanted by a treosulphan-based conditioning regimen. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 20111001
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Haematologica 20110901
Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood 20110421
Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome. Bone marrow transplantation 20110401
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110301
Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan. American journal of clinical oncology 20110201
High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation. Expert opinion on investigational drugs 20101001
Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy. British journal of cancer 20100824
The role of reduced intensity preparative regimens in patients with thalassemia given hematopoietic transplantation. Annals of the New York Academy of Sciences 20100801
Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100710
Treosulfan-based conditioning regimen in a second matched unrelated peripheral blood stem cell transplantation for a pediatric patient with CGD and invasive aspergillosis, who experienced initial graft failure after RIC. International journal of hematology 20091201
Chemotherapy: Topotecan or treosulfan--that is the question. Nature reviews. Clinical oncology 20091001
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecologic oncology 20090801
Diffusion-weighted imaging as predictor of therapy response in an animal model of Ewing sarcoma. Investigative radiology 20090501
Preclinical analysis of treosulfan in combination with total body irradiation as conditioning regimen prior to bone marrow transplantation in rats. Immunopharmacology and immunotoxicology 20090101
Treosulphan as an alternative to busulphan for myeloablative conditioning in paediatric allogeneic transplantation. British journal of haematology 20081201
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. Journal of medicinal chemistry 20081113
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. British journal of haematology 20081101
Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. Cancer chemotherapy and pharmacology 20081001
Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT. Bone marrow transplantation 20081001
Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. Cancer chemotherapy and pharmacology 20080901
Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. American journal of hematology 20080901
Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma. Cancer chemotherapy and pharmacology 20080601
Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. British journal of haematology 20080601
Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. British journal of haematology 20080601
Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia. Anticancer research 20080101
Lessons of war: progress in transplant conditioning regimens. Leukemia & lymphoma 20071201
Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia & lymphoma 20071201
Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. British journal of cancer 20071119
Treosulfan impedes the migration of immunocompetent cells. Journal of neurology 20071001
Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation. Annals of hematology 20070801
Treatment of active secondary progressive multiple sclerosis with treosulfan. Journal of neurology 20070701
Comment on 'determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation' by F.K. Glowka et al. [J. Chromatogr. B 850 (2007) 569-574]. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070615
Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone marrow transplantation 20070401
Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome. Bone marrow transplantation 20070201
Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia. Anticancer research 20070101
Medical treatment of uveal melanoma. Tumori 20070101
Cytotoxic effects of treosulfan on prostate cancer cell lines. Anticancer research 20070101
A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Annals of oncology : official journal of the European Society for Medical Oncology 20061201
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clinical cancer research : an official journal of the American Association for Cancer Research 20060915
Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines. Anti-cancer drugs 20060701
A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma. Melanoma research 20060601
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone marrow transplantation 20060201
Unrelated donor bone marrow transplantation with treosulfan-based myeloablative conditioning for paroxysmal nocturnal hemoglobinuria--successful treatment despite multiple transplant-related risk factors for hemolysis including major Kidd group incompatibility. Bone marrow transplantation 20060101
A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG). European journal of cancer (Oxford, England : 1990) 20060101
Myeloablative and immunosuppressive properties of treosulfan in mice. Experimental hematology 20060101
Evaluation of chemosensitivity of human bone marrow stromal cells--differences between common chemotherapeutic drugs. Anticancer research 20060101
Induction of tolerance across fully mismatched barriers by a nonmyeloablative treatment excluding antibodies or irradiation use. Cell transplantation 20060101
Treosulfan, cyclophosphamide and antithymocyte globulin for allogeneic hematopoietic cell transplantation in acquired severe aplastic anemia. Annals of transplantation 20060101
The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark. Gynecologic oncology 20051201
A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma. Melanoma research 20051001
[Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine]. Deutsche medizinische Wochenschrift (1946) 20050923
Two allogeneic hematopoietic stem cell transplantations without the use of blood-product support. Haematologica 20050901
Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients. British journal of cancer 20050606
Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma research 20050601
Treosulfan and gemcitabine. Journal of cancer research and clinical oncology 20050501
Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone marrow transplantation 20050201
Myeloablative conditioning in myelofibrosis using i.v. treosulfan and autologous peripheral blood progenitor cell transplantation with high doses of CD34+ cells results in hematologic responses - follow-up of three patients. Haematologica 20050201
[Metronomic chemotherapy. Should we change our thinking in the treatment of advanced tumors?]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20050101
Myeloablative conditioning in myelofibrosis using i.v. treosulfan and autologous peripheral blood progenitor cell transplantation with high doses of CD34+ cells results in hematologic responses. A follow-up of three patients. Haematologica 20050101
Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation. International journal of clinical pharmacology and therapeutics 20041101
Treosulfan based conditioning for autologous and allogeneic hematopoietic stem cell transplantation. International journal of clinical pharmacology and therapeutics 20041101
High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. Bone marrow transplantation 20040901
A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours. European journal of cancer (Oxford, England : 1990) 20040901
Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma. Journal of cancer research and clinical oncology 20040701
Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20040401
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 20040115
Toward a myeloablative regimen with clinical potential: II. Treosulfan induces specific skin graft tolerance across haploidentical MHC barriers. Bone marrow transplantation 20040101
Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1. Experimental hematology 20040101
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation. Annals of hematology 20040101
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC cancer 20040101
Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer chemotherapy and pharmacology 20031101
Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. Journal of neuroimmunology 20031101
Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. British journal of haematology 20030901
Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers. Bone marrow transplantation 20030701
Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study. Anti-cancer drugs 20030601
Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). European journal of cancer (Oxford, England : 1990) 20030401
Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation. Bone marrow transplantation 20030301
Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial. Melanoma research 20030201
Treosulfan in the treatment of metastatic melanoma: from chemosensitivity testing to clinical trials. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20030101
Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study. Journal of neuro-oncology 20020901
CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in vitro and in vivo. International journal of oncology 20020701
Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer. Anti-cancer drugs 20020701
Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. British journal of cancer 20020506
The role of gemcitabine-based doublets in the management of ovarian carcinoma. Seminars in oncology 20020201
Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Annals of oncology : official journal of the European Society for Medical Oncology 20020201
Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment. Anti-cancer drugs 20020201
Treosulfan in the treatment of advanced ovarian cancer: a randomised co-operative multicentre phase III-study. Anticancer research 20020101
Progression of Parkinson's disease with impairment of vision under carboplatin/cyclophosphamide therapy for ovarian cancer. Cancer chemotherapy and pharmacology 19980101
Properties